In pharma, here are the top 10 news stories of the year so far, based on web traffic.
Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.
Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.
Sanofi's U.S. diabetes sales team is under a worldwide spotlight--and not because it's time to take a bow.
When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage--which the company admits it did--then that means its rivals, including Eli Lilly and Novo Nordisk, have, too.
Drugmakers are accustomed to grappling with government payers and PBMs over prices. But a pricing fight directly with patients? That's not your everyday occurrence.
Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.
A few things are certain about the Sunshine Act data that hit the Internet Tuesday afternoon. One, it's incomplete. Two, it's controversial. Three, the numbers are pretty staggering, with $3.5 billion in payments to 546,000 doctors and 1,360 research institutions over a 5-month period.
The HHS Inspector General's office says the fine print isn't enough to safeguard against Medicare recipients' coupon use. Drugmakers have to do more--or risk violating antikickback laws.
When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams can get a leg or two up on any follow-up rivals. What's not to like? McKinsey & Co. wanted to find out.